Πέμπτη 26 Ιανουαρίου 2017

@NICEcomms rules sorafenib not cost effective enough for NHS, to be available for patients through Cancer Drugs Fund https://t.co/I2xkWBlu7y

@NICEcomms rules sorafenib not cost effective enough for NHS, to be available for patients through Cancer Drugs Fund https://t.co/I2xkWBlu7y

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://twitter.com/ecancer/status/824595339386687489
via IFTTT

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Δημοφιλείς αναρτήσεις